AUTHOREA
Log in Sign Up Browse Preprints

loading page

Elexacaftor/tezacaftor/ivacaftor Treatment Reduces Airway Inflammation in Cystic Fibrosis
  • +2
  • Richard C. De Vuyst,
  • Erin Bennard,
  • Charissa Kam,
  • Cameron McKinzie,
  • Charles Esther
Richard C. De Vuyst
The University of North Carolina at Chapel Hill Department of Pediatrics

Corresponding Author:[email protected]

Author Profile
Erin Bennard
The University of North Carolina at Chapel Hill Department of Pediatrics
Author Profile
Charissa Kam
University of North Carolina Medical Center
Author Profile
Cameron McKinzie
University of North Carolina Medical Center
Author Profile
Charles Esther
The University of North Carolina at Chapel Hill Department of Pediatrics
Author Profile

Abstract

ETI treatment reduces inflammatory markers and positive bacterial cultures on BAL in PwCF. These findings suggest that ETI has a greater impact on chronic infection and inflammation than ivacaftor alone. However, airway inflammation persists in a fraction of treated individuals, indicating an ongoing need to optimize other treatments in a subset of patients.

Peer review status:ACCEPTED

22 Dec 2022Submitted to Pediatric Pulmonology
Show details
Hide details
22 Dec 2022Review(s) Completed, Editorial Evaluation Pending
22 Dec 2022Submission Checks Completed
22 Dec 2022Assigned to Editor
28 Dec 2022Editorial Decision: Revise Minor
04 Jan 20231st Revision Received
10 Jan 2023Submission Checks Completed
10 Jan 2023Assigned to Editor
10 Jan 2023Review(s) Completed, Editorial Evaluation Pending
18 Jan 2023Reviewer(s) Assigned
25 Jan 2023Editorial Decision: Accept